
Drug-resistant tuberculosis: how to interpret rapid molecular test results

The Defeat NCD Partnership

Type: Course

Emplacement: En ligne

Durée: 5 Heures

Zone du programme: Other

Site internet: https://whoacademy.org/coursewares/course-v1:WHOAcademy-Hosted+H0015EN+H0015EN_...

Prix: 0.00 \$US

Personne de référence de

l'évenement: globalhealth@unitar.org

ARRIÈRE PLAN

The course is particularly relevant for laboratory experts who perform drug-susceptibility testing (DST) for TB and clinicians who use DST results in their routine clinical practice. We hope this training will help refine your practice, thereby strengthening the global capacity to diagnose DR-TB.

Addressing drug-resistant tuberculosis (DR-TB) is a global priority to accelerate progress towards the elimination of TB. In many countries, patients with DR-TB are either not diagnosed at all or receive a delayed diagnosis, leading to further spread and increased severity of the disease. WHO-endorsed rapid molecular tests have dramatically improved the speed and quality of diagnosis of DR-TB and should be adopted more widely, complemented with phenotypic alternatives where necessary.

OBJECTIFS DE L'ÉVÉNEMENT

This online training toolkit by the [European Laboratory Initiative for TB, HIV and Viral Hepatitis](#) provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB).

CONTENU ET STRUCTURE

Implement WHO guidelines for the interpretation of Xpert, Ultra, FL-LPA and SL-LPA for gDST.

MÉTHODOLOGIE

The content of this course has been validated, verified, and is owned by the WHO Regional Office for Europe.

This course is not a WHO Academy co-produced course. In case of any concerns or feedback on the course content, please share your feedback in the survey form at the end of this course.

AUDIENCE VISÉE

The course is particularly relevant for laboratory experts who perform drug-susceptibility testing (DST) for TB and clinicians who use DST results in their routine clinical practice. More specifically, it covers the latest guidance for the interpretation of rapid molecular assays for DR-TB by Cepheid (GeneXpert

MTB/RIF and GeneXpert MTB/RIF Ultra) and Hain Lifescience (GenoTypeMTBDRplus VER 2.0 and GenoTypeMTBDRsI VER 2.0).